Skip Navigation


JAC Advance Access originally published online on July 30, 2006
Journal of Antimicrobial Chemotherapy 2006 58(4):778-783; doi:10.1093/jac/dkl314
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/4/778    most recent
dkl314v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gualtieri, M.
Right arrow Articles by Leonetti, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gualtieri, M.
Right arrow Articles by Leonetti, J.-P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

In vitro activity of a new antibacterial rhodanine derivative against Staphylococcus epidermidis biofilms

Maxime Gualtieri1, Lionel Bastide2, Philippe Villain-Guillot1, Sylvie Michaux-Charachon3,4, Jaqueline Latouche1 and Jean-Paul Leonetti1,*

1 CNRS UMR 5160, Centre de Pharmacologie et Biotechnologie pour la Santé, Faculté de Pharmacie Montpellier, France 2 Selectbiotics, Nîmes France 3 INSERM U-431, Faculté de Médecine Nîmes, France 4 Laboratoire de Bactériologie, CHU de Nîmes Nîmes, France

Received 24 April 2006; returned 8 June 2006; revised 7 July 2006; accepted 7 July 2006

*Corresponding author. Tel: +33-467-548-607; Fax: +33-467-548-610; E-mail: jp.leonetti{at}cpbs.univ-montp1.fr

Objectives: Staphylococcus epidermidis biofilms form at the surface of implants and prostheses and are responsible for the failure of many antibiotic therapies. Only a few antibiotics are relatively active against biofilms, and rifampicin, a transcription inhibitor, is among the most effective molecules for treating biofilm-related infections. Having recently selected a new potential transcription inhibitor, we attempted to evaluate its efficacy against S. epidermidis biofilms.

Methods: Biofilm-forming S. epidermidis strains were grown planktonically or as biofilms and their susceptibility to this transcription inhibitor was compared with reference antibiotics with different mechanisms of action.

Conclusions: Our results demonstrate that this new molecule is active; its effects are fast and kinetically related to those of rifampicin, but unlike rifampicin it does not select for resistant bacteria.

Keywords: RNA polymerase , inhibitors , antibiotics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
P. Villain-Guillot, M. Gualtieri, L. Bastide, and J.-P. Leonetti
In Vitro Activities of Different Inhibitors of Bacterial Transcription against Staphylococcus epidermidis Biofilm
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3117 - 3121.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.